Metagenomi (MGX) Projected to Post Quarterly Earnings on Tuesday

Metagenomi (NASDAQ:MGX) is anticipated to release its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect Metagenomi to post earnings of ($0.60) per share and revenue of $5.9030 million for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:00 PM ET.

Metagenomi (NASDAQ:MGX) last released its quarterly earnings data on Thursday, March 5th. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.02). The firm had revenue of $3.91 million for the quarter, compared to the consensus estimate of $7.33 million. Metagenomi had a negative net margin of 348.54% and a negative return on equity of 47.14%. On average, analysts expect Metagenomi to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Metagenomi Trading Up 0.7%

NASDAQ:MGX traded up $0.01 on Tuesday, reaching $1.42. 23,108 shares of the stock traded hands, compared to its average volume of 232,190. The company has a market capitalization of $53.46 million, a price-to-earnings ratio of -0.60 and a beta of 0.63. Metagenomi has a 12 month low of $1.25 and a 12 month high of $3.95. The company’s fifty day simple moving average is $1.46 and its 200 day simple moving average is $1.72.

Analyst Ratings Changes

A number of research firms have weighed in on MGX. Wall Street Zen lowered shares of Metagenomi from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Weiss Ratings raised shares of Metagenomi from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Metagenomi presently has an average rating of “Moderate Buy” and an average target price of $10.00.

Hedge Funds Weigh In On Metagenomi

A number of institutional investors and hedge funds have recently made changes to their positions in MGX. Renaissance Technologies LLC boosted its holdings in shares of Metagenomi by 276.3% in the fourth quarter. Renaissance Technologies LLC now owns 628,400 shares of the company’s stock worth $1,018,000 after buying an additional 461,400 shares during the last quarter. Jane Street Group LLC boosted its holdings in shares of Metagenomi by 341.6% in the fourth quarter. Jane Street Group LLC now owns 433,859 shares of the company’s stock worth $703,000 after buying an additional 335,604 shares during the last quarter. Norges Bank purchased a new position in shares of Metagenomi in the second quarter worth approximately $373,000. Bridgeway Capital Management LLC boosted its holdings in shares of Metagenomi by 102.1% in the fourth quarter. Bridgeway Capital Management LLC now owns 395,800 shares of the company’s stock worth $641,000 after buying an additional 200,000 shares during the last quarter. Finally, Two Sigma Investments LP boosted its holdings in shares of Metagenomi by 1,394.4% in the third quarter. Two Sigma Investments LP now owns 207,528 shares of the company’s stock worth $492,000 after buying an additional 193,641 shares during the last quarter.

Metagenomi Company Profile

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.